Study

Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. – Cost Effective Supplements

Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.

Quick navigation


http://www.ncbi.nlm.nih.gov/pubmed/21775755


Conclusion of this study

Four-year treatment with ALA in mild-to-moderate DSPN did not influence the primary composite end point but resulted in a clinically meaningful improvement and prevention of progression of neuropathic impairments and was well tolerated. Because the primary composite end point did not deteriorate significantly in placebo-treated subjects, secondary prevention of its progression by ALA according to the trial design was not feasible.


Supplements analyzed in this study

Alpha-Lipoic Acid

Health conditions analyzed in this study

Diabetic Nerve Problems


Moderately Positive
Alpha-Lipoic Acid


Functions related to this study

Insulin control


Moderately Positive
Alpha-Lipoic Acid

Weight loss


Slightly Positive
Alpha-Lipoic Acid


Body systems related to this study


Digestive System

Endocrine System
Scroll to top